How cost-effective are sirolimus-eluting stents when compared with bare-metal stents?
Raúl Moreno
Correspondence Interventional Cardiology Hospital Clínico San Carlos, Martín Lagos, 28040 Madrid, Spain
Email raulmorenog@terra.es
This article has no abstract so we have provided the first paragraph of the full text.
The sirolimus-eluting CYPHER® stent has been evaluated against BMSs in a number of randomized trials that have included 
2,500 patients. It has consistently reduced restenosis and, more importantly, the need for revascularization. Similar results have been shown with the TAXUS® stent (Boston Scientific, Maple Grove, Minnesota).
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
